Brentuximab vedotin-associated diabetic ketoacidosis: a case report-Reference-Cited by-同舟云学术

Brentuximab vedotin-associated diabetic ketoacidosis: a case report

Published:2022-07-16 Issue:1 Volume:43 Page:120-124
ISSN:0973-3930
Container-title:International Journal of Diabetes in Developing Countries
language:en
Short-container-title:Int J Diabetes Dev Ctries

Author:

Köksalan Damla^ORCID,Sözen Mehmet^ORCID,Selek Alev^ORCID,Gezer Emre^ORCID,Cantürk Zeynep^ORCID,Çetinarslan Berrin^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://link.springer.com/content/pdf/10.1007/s13410-022-01116-w.pdf

Reference10 articles.

1. Nyenwe EA, Kitabchi AE. The evolution of diabetic ketoacidosis: an update of its etiology, pathogenesis and management. Metabolism: Clinical and Experimental. 2016;65:507–21.

2. Ansell SM. Hodgkin Lymphoma: Diagnosis and Treatment. In: Hodgkin lymphoma: diagnosis and treatment. In: Mayo Clinic Proceedings. Elsevier Ltd; 2015. p. 1574–83.

3. Makita S, Maruyama D, Tobinai K. Safety and efficacy of brentuximab vedotin in the treatment of classic Hodgkin lymphoma. OncoTargets and Therapy. 2020;13:5993–6009. https://doi.org/10.2147/OTT.S193951.

4. Katz J, Janik JE, Younes A. Brentuximab vedotin (SGN-35). Clinical Cancer Research. 2011;17:6428–36. https://doi.org/10.1158/1078-0432.CCR-11-0488

5. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Brentuximab Vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812–21. https://doi.org/10.1056/NEJMoa1002965

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Severe insulin resistance in a patient with diabetes after treatment with brentuximab vedotin;BMJ Case Reports;2024-04

2. Severe Insulin Resistance in a Patient Treated With Nivolumab and Brentuximab-Vedotin for Hodgkin Lymphoma;JCEM Case Reports;2023-11

3. Drug-induced hyperglycemia and diabetes;Therapies;2023-10

4. Brentuximab-vedotin;Reactions Weekly;2023-06-10

5. Diabetic Ketoacidosis and Profound Insulin Resistance From Brentuximab Vedotin;Cureus;2023-03-05